Making a difference in patients’ lives: Leading provider for critical care 

The healthcare space is rapidly changing: Demographic shifts, AI advancements, and evolving patient needs. With our products and services at Fresenius Kabi, we are uniquely positioned to support patients right at the critical points in care. Whether in the emergency room, where quick decisions in diagnoses and choosing the right patient path are key, in the operating room with precise procedures, or in the intensive care unit, where stabilizing patients and safely guiding them out of critical situations is crucial. 

Throughout 2024, Fresenius Kabi has significantly strengthened its role as a leading provider of healthcare products and therapies for critically and chronically ill patients: by investing in key growth areas and making a difference in patients’ lives.

Our commitment to delivering high-quality, innovative healthcare solutions is fueled by the dedication of our valued employees. Striving to become an Employer of Choice is a natural extension of this commitment and with that, ensuring that patients receive the highest standard of care. The Top Employer recognition underscores our efforts to deliver on our promise of excellence across all aspects of our organization.

2024 success stories: 

Kabi’s strategy is paying off

Fresenius Kabi is strategically well-positioned with IV generics and fluids as the basis, complemented by the three growth vectors: Biopharma, Clinical Nutrition, and MedTech. Introduced in 2021, the strategic approach of focusing on the three growth vectors while strengthening the volume-driven IV generics business is paying off: The growth vectors’ share of EBIT is steadily increasing. With Kabi’s broad and unique portfolio, we are making a difference in patients’ lives by investing in areas that matter: in Nutrition, MedTech, and Biopharma. The three growth vectors are now the largest value drivers at Fresenius - a trend that is set to continue with contributions from Biopharma, new product launches in Nutrition, and the improving MedTech margin.

Growing access to essential and affordable medicine

By continuously expanding our generics business, we strengthen our role to provide access to essential and affordable medicine for a growing amount of people. We ensure the supply for critically and chronically ill patients. In 2024, we expanded our portfolio with Lacosamide, a generic for treating epilepsy in intensive care, and Thiotepa, a cancer therapy in Europe. In the U.S., launching Cyclophosphamide, an oncology product, and Cetrorelix Acetate, used for women’s health, will enhance further cost-effective treatment options.

Uniquely positioned with both parenteral and enteral nutrition

Clinical nutrition is a growing business with attractive margins, and we are uniquely positioned globally: We cover both parenteral and enteral nutrition. In 2024, we continuously expanded our offering. In Europe, we launched Peditrace Novum, a parenteral micronutrient formula for pediatric use. In addition, the first launches of ‘Foods for Special Medical Purposes’ (FSMP) in China offer new growth opportunities and improve access in China to innovative nutrition formulas. 

Driving a new generation of generics

Affordability is key for IV generics and biopharmaceuticals! Our Biopharma portfolio plays an important role here: With Kabi’s biosimilars pipeline – biologically produced imitation products – we drive a new generation of generics. Five products are already on the market, including the launch of Tyenne, the first tocilizumab biosimilar for inflammatory and immune diseases launched in 20 countries globally. Additionally, Otulfi, our ustekinumab biosimilar, received FDA and EMA approval in 2024 and was just launched in March 2025. Biosimilars are significantly more affordable than biologics, improving access to cutting-edge treatments for acute and chronic diseases. With the biosimilar market expected to grow by 20% in the next five years, Kabi’s portfolio is well-positioned to capitalize on this expansion.

In this effort, mAbxience is an important platform for us: we are working on scaling and advancing vertical integration. With mAbxience, we have acquired a leading biopharmaceutical company that develops and manufactures biosimilars and biologics, with end-to-end capabilities in state-of-the-art facilities in Spain and Argentina. mAbxience is not only increasing our pipeline of molecules but it also complements our service offering with the highly attractive ‘Contract Development and Manufacturing Organization’ (CDMO) business. All this is contributing to 2025 and beyond!

Strengthening global partnerships 

In MedTech, we focus on achieving the highest precision in patient care and therapy. We have strengthened our medical technology business through strong partnerships with leading companies and investments in state-of-the-art manufacturing technologies. We collaborate with Cellular Origins to automate the cell processing in cell and gene therapies. Additionally, we have completed a clinical study using enhanced software for improved plasma collection. The rollout of our smart pump system, Ivenix, in the U.S is progressing as planned, and the feedback has been very promising.

Global footprint, local strengths

While Fresenius Kabi serves global markets, our regional and local presence is one of Kabi’s strengths. This balanced strategy and a ‘local for local’ approach to customers can be seen in our manufacturing network, which spans from Wuxi in China to Friedberg in Germany to Grand Island, Melrose Park, and Wilson in the United States. A prime example for this approach is the U.S.: more than 70% of our pharmaceuticals sold to U.S. customers are produced in the country. We manage the entire supply chain, from manufacturing, logistics to warehousing and have invested in our distribution network and located them so those sites can ship product to customers within 24 hours. Through this manufacturing and distribution network, we can respond effectively in critical situations, such as recent shortages of infusion and irrigation solutions. These solutions are essential for hospital operations, and Kabi’s quick, flexible response helped keep healthcare systems running worldwide – thanks to our global production capabilities!

Innovation in hospitals is key: Europe’s market-leading hospital network

Fresenius Helios is Europe’s leading private network of hospitals and outpatient clinics and is continuously expanding its role. Every year, about 26 million patients choose Helios for their medical treatment. With Helios in Germany and Quirónsalud in Spain, the group operates about 140 hospitals and more than 350 medical care centers. Many of our clinics in Spain and Germany are ranked among the best and receive top marks from patients.

Throughout 2024, Fresenius Helios has continuously expanded its role as Europe's leading private health care provider, advancing therapies and care on many levels: through high-quality and innovative treatments.

2024 success stories: 

Driving medical excellence across clinics 

Fresenius Helios demonstrates on a broad scale what medical progress looks like: In 2024, Forbes España business magazine named seven Quirónsalud hospitals among the 25 leading healthcare centers in Spain with Jiménez Díaz Foundation University Hospital ranked number 1. More than 700 facilities were examined. This award was among others justified by its clinical research, technological innovations, leading medical staff, and diverse range of services. The latest technologies for example include magnetic resonance-guided focused ultrasound (MRgFUS) to treat deep brain regions in movement disorders like Parkinson’s disease or essential tremor.

At Helios in Germany, we continue to advance medical progress with the expansion of the medical excellence clusters. This approach involves specializing and pooling medical services in one location driving treatment volume and increasing quality. Fostering this innovative strength and commitment was also one of the key topics of Helios clinical congress in Berlin, where about 1,700 employees from various locations and hierarchical levels discussed solutions in healthcare.

Promising breast cancer study

Fresenius Helios is very successful in conducting clinical studies on innovative treatment approaches. One important area is oncology: Around 13 out of 100 women develop breast cancer in the course of their lives. A long-term clinical trial involving 1,500 breast cancer patients at Fresenius Helios in Germany was published in the New England Journal of Medicine. The study revealed that “antibody-drug conjugates”, which target cancer cells with precision, significantly improved treatment outcomes. Impressively, nine out of ten patients with an aggressive form of breast cancer were still alive after eight years.

Advancing digital solutions and AI

Our colleagues at Quirónsalud in Spain are pioneering digital solutions with the self-developed ecosystem “Casiopea”. Quirónsalud has created a fully digitally networked and integrated healthcare system that supports and improves the patient journey in hospital and beyond. The “digital hospital” is already a reality. With Casiopea, all processes relating to treatment are fully controlled. The system is aimed at both patients and medical staff and makes all data centrally available to everyone in one place. This allows to direct patient flows correctly from the outset, prevent unnecessary waiting times. Inpatients use the app for example to check, track the current course of treatment in real time, access documentation and to communicate with their doctors. They, in turn, plan the entire treatment, share findings, assign surgery appointments, and create the medication plan. This fully integrated process control with Casiopea, its many years of use in the care of millions of patients is unique in Europe. Today, seven million people use the Casiopea digital patient portal! 

AI applications, both self-designed and customized, are increasingly integrated into routine practices across hospitals in Spain and Germany. A recent pilot project added the “Scribe” application to Casiopea, which automates the transcription, interpretation, data entry and creation of a doctor’s letter by “ambient listening” during doctor-patient conversations. AI strongly enhances understanding of procedures and documentation. Most people are familiar with the scenario of medical visits: sitting in front of the doctor who types into their computer, almost glancing at the patient while talking. This is where AI steps in records the doctor-patient conversation and organizes it into a readable format. Both patient and doctor can review the written record together, improving the quality of the interaction and allowing for a more focused and engaging conversation. This innovation enhances consultation quality and saves time. After six months, more than 1,600 doctors are already using the system, which has been used for more than 112,000 consultations. The goal is to have more than 8,000 doctors using the system in the first months of 2025, which corresponds to 60 percent of the company’s doctors.

New facilities in Germany and Spain

With the opening of the Helios HSK clinic in Wiesbaden, Germany, we have built one of the most modern hospitals in Germany for patient care treating more than 175,000 patients every year. With this investment we send a signal: for excellent medical care! In Spain, we have opened a new Quirónsalud hospital in Zaragoza, offering over 30 medical specialties and state-of-the-art technologies!

Fostering innovation and research

At the heart of “Rejuvenate” – the next phase of our #FutureFresenius transformation – are innovation, research and development, and the use of state-of-the-art technologies to improve patient care. Digitally supported business processes, an ecosystem for healthcare data, and a strong innovation culture within the company are just a few points we will focus on in 2025 and beyond.